Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes
- First Online:
- Cite this article as:
- Fendler, W., Baranowska, A.I., Mianowska, B. et al. Acta Diabetol (2012) 49: 363. doi:10.1007/s00592-011-0332-7
- 1.3k Downloads
Treatment with continuous subcutaneous insulin infusion (CSII) allows a large degree of treatment individualization and intensification in children with diabetes. The study’s aim was to evaluate the impact of treatment with CSII on glycated haemoglobin level (HbA1c) in children with diabetes and investigate whether introduction of CSII is associated with an increased risk of acute complications of diabetes. Patients treated throughout the recruitment period exclusively with multiple daily injections (MDI) were matched for duration of diabetes and HbA1c level at baseline with patients treated exclusively with CSII in a 1:1 group ratio (n = 223 and 231 for MDI and CSII, respectively). The CSII group showed lower HbA1c after the observation period (7.98 ± 1.38 vs. 7.56 ± 0.97; P = 0.002). HbA1c variability measured as standard deviations of average values was also lower in the CSII group (0.73 ± 0.45 vs. 0.84 ± 0.54; P = 0.049). The rate of hospitalization due to acute events was similar in both groups (14.7/100 vs. 14.0/100 person/years in the MDI and CSII group, P = 0.72). Duration of hospital stay per year was on average 1.25 days shorter in the CSII group (P = 0.0004), but the risk of acute complications resulting in hospitalization did not differ between the groups (hazard ratio (HR) 1.16; 95% confidence interval (95% CI) 0.68–1.63). The most significant risk factor for hospitalization due to acute complications was baseline HbA1c concentration (HR 1.25; 95% CI 1.14–1.37). In conclusion, CSII treatment may improve glycemic control and reduce its variability. Change of MDI to CSII does not alter the risk of hospitalization and may reduce the annual duration of hospitalization in children with diabetes.
KeywordsInsulin delivery systems Complications of diabetes Paediatric diabetes Healthcare organization
In Poland, the incidence of type 1 diabetes in the population below 15 years of age tripled during the last three decades [1, 2]. During that time, new methods of diabetes management such as rapid and long-acting insulin analogues, continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems have been implemented. The primary goals of these technologies were to improve metabolic control, decrease the frequency of acute and chronic diabetes complications and minimize the overall healthcare burden. Numerous studies have unequivocally shown that better metabolic control decreases chronic diabetes-related complications . Although the quality of paediatric diabetes care has markedly improved, hospital visits related to acute complications still constitute a serious burden for the healthcare system . Several studies in children and adolescents have shown improvements in terms of better metabolic control, reduced rates of complications and better quality of life [5, 6, 7, 8, 9, 10]. Patients treated with CSII are not, however, free from acute complications, e.g. rates of diabetic ketoacidosis or hypoglycaemic events, and the hospital burden of diabetes in such patients is still considerable . Moreover, some reports are in favour of additional precautions during the switching period, with regard to the type of insulin used, its dose and patient’s age .
The aim of this study was to evaluate the impact of treatment with CSII on the metabolic control (expressed as glycated haemoglobin level—HbA1c) and its variability in children with diabetes. The study also investigated whether the introduction of CSII was associated with altered risk, or rates, of acute complications of diabetes in prolonged treatment.
Patients and methods
Throughout the observation period, the study centre treated >90% of children with diabetes within the Lodz administrative region, inhabited by 2.6 million people. This was a prospective observational study based on a standardized computerized, manually curated database of discharge summaries of all patients with type 1 diabetes hospitalized at the study centre from January 2002 to December 2010. The number of patients treated within the centre increased from 520 to 632 throughout the study period. The centre’s diabetes epidemiology database used in nationwide and regional trials [2, 13] covers all patients registered at the hospital discharge summaries database, which ruled out the possibility of missing patients with diabetes treated in the region. The CSII group was collected without any specific restrictions concerning the patients; the decision to introduce CSII was based on the patient’s or their parents’ willingness to change the treatment in view of more freedom in food intake and lifestyle, and on the clinical judgment of the physician. Clinical indications for CSII were high HbA1c levels (above 8–8.5%), dawn phenomenon, frequent hypoglycaemia (at least two episodes per year of severe hypoglycaemia with need for intervention of another person or loss of consciousness), concomitant chronic illnesses or willingness to improve the patient’s quality of life. The CSII group was collected between January 2002 and December 2008. Subsequent follow-up was continued until December 2010.
Patients treated throughout the recruitment period exclusively with multiple dose injections (MDI) were matched retrospectively for duration of diabetes and baseline HbA1c level to the CSII group to ensure a 1:1 group ratio. Propensity score matching was attempted; it is a technique aimed at the elimination of group allocation bias through calculation of individual probability of being assigned to the treatment or control group on the basis of covariates associated with group allocation [14, 15]. However, as it would lead to imbalanced group numbers in terms of individual patients (Electronic Supplementary Material, Table 1), covariate matching was used instead. Criteria for inclusion into the analysis were set as following: type 1 diabetes diagnosis according to WHO criteria, lack of obesity (<90th centile of body mass index for age and sex), treatment with insulin with a mean daily dose >0.3 units/kg, age at onset greater than 12 months, duration of diabetes >1 year and presence of at least one anti-islet autoantibody at onset (islet cell antibody, anti-GAD, insulin autoantibody or IA2). Patients with type 2 diabetes, cystic fibrosis or confirmed monogenic diabetes were excluded from both groups. Patients who changed treatment from CSII to MDI, started CSII therapy prior to January 2002 or switched their treatment regimen twice during the observation period were not considered eligible for the analysis. Patients who were diagnosed with type 1 diabetes during the observation period but were not subsequently treated as inpatients or outpatients at the study Centre were excluded from the analysis (n = 118). During the follow-up, scheduled hospital admissions of patients with type 1 diabetes have been carried out every 2.5 year (to perform screening tests for chronic diabetic complications, common autoimmune diseases and for re-education). Only acute hospitalizations were considered in this analysis. Considering the access to the treatment, the cost of insulin treatment other than with long-acting insulin analogues was fully reimbursed by the state throughout the study period. Costs of insulin pumps and tubing for children were covered either by a non-profit organization (the Great Orchestra of Christmas Charity) or by the National Health Fund.
The primary outcome of the study was the risk of acute hospitalization due to hypo- and/or hyperglycaemia and acute hospitalization for any reason. Hospitalization due to hypoglycaemia was defined as hospital admission due to: (1) symptoms typical for hypoglycaemia that improved after oral/parenteral glucose or parenteral glucagon administration or (2) documented low capillary/venous blood glucose concentration, both acknowledged/recognized by the admitting physician as requiring hospitalization because of the severity (severe hypoglycaemia) or recurrence of symptoms (i.e. due to gastrointestinal infection or insulin overdose). Hospitalization due to hyperglycaemia was defined as hospital admission due to: (1) ketoacidosis, (2) high blood glucose levels (over 250 mg/dl) persisting for at least 12 h and not improving in the ambulatory setting or (3) incorrect glycaemic control as reflected by high HbA1c level assessed by the guiding diabetologist as not acceptable for the individual patient (typically over 8%—depending on patient’s age, history of experienced severe hypoglycaemia, concomitant illnesses and previous metabolic control). The MDI group used various combinations of long-acting analogues, NPH insulin, short-acting analogues or human insulin. No subgroup analyses based on insulin type used were possible, as changes were frequent, occurred multiple times in numerous patients and may have been dependent on the availability of particular insulin preparations.
Measured outcomes included the following: HbA1c level measured at the moment of CSII introduction or matching (for MDI-treated patients) and at the end of the observation period or censoring due to reaching the age of 18 years (mean HbA1c 8.05 ± 1.30); meeting the therapeutic goal of <7.0% of HbA1c ; number and duration of hospital visits calculated for the whole observation period; time to first hospitalization due to acute causes—for this purpose, patients who reached 18 years of age or had no acute visits since enrolment before the study closing date were treated as censored observations.
Glycated haemoglobin measurements
Throughout the whole study period, the laboratory method for the assessments of HbA1c was consistent. HbA1c assays were performed by ion-exchange high-performance liquid chromatography (HPLC) using the Bio-Rad VARIANT™ Hemoglobin A1c Program (Bio-Rad Laboratories, Inc. Hercules, California, USA). The VARIANT™ Hemoglobin A1c Program has been certified by the National Glycohemoglobin Standardization Programme (NGSP) as meeting the DCCT standard. The within-run coefficient of variation (CV) determined by the manufacturer was 1.05% for people without diabetes and 0.94% for people with diabetes; the between-run CV was 1.61 and 1.16% for people without diabetes and for people with diabetes, respectively. Blood samples were collected with HbA1c Capillary Collection System (Bio-Rad Laboratories, Inc. Hercules, California, USA) and analysed according to the manufacturer’s protocol.
To determine whether residual beta cell function was similar between the two groups, C-peptide levels were measured at baseline whenever possible using radioimmunoadsorption assays (IRMA-C-PEP, CIS Bio International). Both intra- and interassay CV for this assay equalled 4.9 and 5.1%, respectively, according to the manufacturer. Minimum detectable C-peptide level equalled 0.036 mmol/ml, and its concentrations in a group of 40 healthy individuals were within the 0.35–1.17 mmol/ml range.
Analysis of covariance (ANCOVA) models were used for the evaluation of mean HbA1c and its variability (expressed as standard deviations—SD) with adjustment for duration of diabetes. Correlations were evaluated using Pearson’s correlation coefficient. Final HbA1c values were additionally converted to percentile values of patients treated within the centre to assess the profile of each group with respect to metabolic profile of the clinic. For comparisons of percentiles of HbA1c and the number of hospital days per patient-year, the Mann–Whitney U test was applied with medians and interquartile ranges (IQRs) used for result presentation. The log-rank test was used for uncorrected comparison of survival without acute complications depending on treatment type. To adjust for covariates, a multivariate proportional hazard regression analysis including data on patient’s sex, initial HbA1c, age and duration of diabetes at enrolment was developed. A P value of <0.05 was considered to be the threshold of statistical significance.
Comparison of baseline characteristics
Baseline characteristics of the study group
Age at enrolment [years]
Duration of diabetes at enrolment [years]
Daily insulin dose [U/kg]
C-peptide level [ng/ml] (normal range >0.35 ng/ml)
HbA1c at enrolment [%] (normal range 4.3–5.7%)
Comparisons of metabolic outcomes
Percentile comparisons performed to ascertain the relative improvement of HbA1c showed that the CSII group ranked significantly better, with median percentile of final HbA1c equal to 45% (IQR 24–68%) in comparison with 59% (IQR 29–81%) noted in MDI-treated individuals (P = 0.001).
The percentage of patients reaching the therapeutic goal of <7% of HbA1c equalled 32.9% in the CSII and 25.7% in the MDI group (P = 0.12).
Comparisons of hospital burden in children treated with CSII or MDI
Multivariate Cox regression analysis of factors affecting the risk of acute hospitalization
95% Confidence Interval
Baseline HbA1c level [%]
Treatment with CSII
Age at enrolment
Duration of diabetes
Baseline C-peptide level
Duration of hospital stay and number of visits for any reason or emergency ones
Days in hospital per year
Days in hospital per year due to emergency visits
Benefits gained through CSII application included a slower deterioration of HbA1c values, evidenced by an increasing difference in initial and final HbA1c levels depending on CSII or MDI treatment. Curiously, baseline characteristics of the presented study group suggest that the analysed patients could have been in fact better controlled than those in the STAR 3 trial , (mean HbA1c levels 7.6 ± 1.5 vs. 8.5 ± 0.6) making it more difficult to obtain a statistically significant improvement of HbA1c. Stable HbA1c levels despite ageing and duration of diabetes observed in CSII-treated individuals in this trial do, however, mirror the beneficial effect of the STAR 3 participants. Final mean HbA1c levels in the paediatric group in STAR 3 equalled 7.7%, whereas in the presented cohort the final mean HbA1c reached 7.6%. Despite the methodological differences and application of different insulin pumps (the STAR 3 pumps were sensor-augmented), results confirming the overall benefit of CSII seem surprisingly convergent. Moreover, the difference in final HbA1c levels was similar to that reported in a recent meta-analysis by Monami et al.  who showed a −0.3% reduction in favour of the CSII group. This may be interpreted as showing that CSII offers an advantage in terms of better metabolic control, but the improvement will seldom exceed 0.5% in long-term observation. Further improvements could theoretically be gained through the use of more sophisticated therapeutic approaches such as dual wave bolus (DWB) [18, 19]. However, due to the magnitude duration of observation, changing patient preferences in using DWB, the authors refrained from introducing this factor to stratify the CSII group.
Although CSII was shown to offer better metabolic control, this effect did not translate into the risk of acute hospitalizations. A lack of difference in this endpoint suggested that educational measures undertaken during the switching phase were adequate and did not result in shortened time to first hospital visit due to acute complications. Finally, rates of hospitalizations due to acute visits did not differ between the groups which confirmed that no additional risk of hypoglycaemia or ketoacidosis was created by CSII treatment, in contrast to earlier studies on that matter .
The obviously non-random allocation of patients is the main limitation of the study and a potential for bias, but the lack of differences in baseline HbA1c and duration of diabetes justified this approach and made the groups comparable. The authors performed covariate matching for baseline HbA1c and duration of diabetes which lead to balanced group numbers, apart from the age difference, which was adjusted for in multivariate comparisons. The perfect design—a randomized study—for a group of such magnitude would be unfeasible from an organizational point of view. Recently published results of an ambitious project on the use of sensor-augmented CSII (the STAR 3 trial)  covered 156 children allocated to either CSII or MDI. The observational approach with matching of MDI and CSII patients used in this study, although potentially biased by non-random selection, allowed the authors to include a study group of 454 individuals, yielding greater statistical power and robustness in terms of adjusted effects estimation. The fact that the differences in HbA1c persisted after correction for confounding factors further increased the credibility of presented findings.
Presented patients were followed for 3 years, which allowed the authors to evaluate the effect of CSII on hospitalization rates and variability of HbA1c. The latter effect of CSII may be clinically important, as lower SD of HbA1c is a result of reduced rates of prolonged periods glycaemia maintained alternatively within the high or low concentration range. CSII treatment was already reported to reduce blood glucose variability in a meta-analysis authored by Pickup et al. . Although variability of HbA1c is not yet considered an endpoint in diabetes trials, it was proven to increase the risk of long-term complications of diabetes in DCCT data analysis . Therefore, interventions aimed at its reduction could be perceived as being potentially beneficial and therefore worthy of further interest.
Results of this study in terms of HbA1c changes due to CSII treatment were in line with those obtained by Jakisch et al.  who in a group of 434 matched pairs of patients with type 1 diabetes, showed an improvement of HbA1c during the first year of the study. In their study however, the difference disappeared after 3 years of observation, showing that the benefit could be attributed to the “novelty” effect. In the presented study, the effect seemed to persist throughout the observation period of similar duration (mean 3.05 years), possibly due to different educational approaches or changes in patients’ ability to cope with diabetes and its management.
Persistent residual function of the beta cells could also contribute to better metabolic control in CSII-treated patients. However, as only 12% of analysed patients had C-peptide levels within normal range and no difference was detected between the groups, it seems very unlikely that residual beta cell function contributed significantly to the observed outcomes.
Over 30% of patients required at least one hospitalization due to acute complications during the observation period. This could result in a bias of study results, as the older patients may have left the group after shorter observation periods before developing acute complications, while younger ones could be observed for longer periods of time increasing their chances of acute hospitalization. However, the rate of acute hospitalizations per 100 patient/years was nearly identical between CSII and MDI-treated patients, as was the case for risk of the first acute hospitalization, which allowed the authors to assume that the risk of being hospitalized due to acute conditions is the same with MDI or CSII treatment. CSII did, however, promote shorter overall hospital stays per year by nearly 25%, which could result in an economic benefit from this type of treatment.
The rate of severe hypoglycaemia in an outpatient setting among children with diabetes is hard to estimate, as reported rates range widely from 6.63 events per 100 patient-years, reported by the PedPump study which included patients from Poland , to 62 per 100 patient-years reported earlier by Levine et al. . In the Hvidore study group, which formulated the criteria for assessment of hypoglycaemic events used in the above-mentioned studies, the rate of severe hypoglycaemia equalled 22 per 100 patient-years . Introduction of CSII treatment was shown to reduce the overall rate of hypoglycaemia  and was expected to result in a reduction in hospitalizations due to this complication in the studied group. The observed lack of differences in this outcome could result from one of the limitations of the presented study—the authors were unable to objectively collect and analyse data from outpatient clinics and match them with those from the hospital database. All patients and their parents could contact their attending diabetologists by phone and did so in critical situations including severe hypoglycaemic episodes, but precise recall of the overall and individual numbers of such episodes was not possible. As a result, the authors were unable to determine actual rates of hypoglycaemia not resulting in hospital admission. Hospitalizations due to hypoglycaemia, however, constituted 25% of all acute diabetes-related hospital visits in our study group, which is a similar value range as that noted in an earlier study by Palta et al.  The authors reported a rate of 1.9 per 100 patient-years hospital admissions due to hypoglycaemic events in patients with diabetes aged 0–29, which amounted to 21% of all hospital admissions of their cohort. Thus, it seemed that the group presented within this study did not deviate significantly from those reported in previous reports in terms of hypoglycaemia incidence, with no evident benefits gained through the introduction of CSII.
Confirmation of the fact that baseline HbA1c was the main risk factor for hospitalization due to acute complications may be one with considerable clinical implications. This association was previously reported in epidemiologic studies on children with diabetes [25, 27, 28]. One could therefore assume that patients with initially worse metabolic control should be a group of particular interest for the physician, as any intervention leading to the improvement of HbA1c could yield beneficial effects in terms of reducing the risk of acute hospitalizations. The percentage of patients reaching the therapeutic goal of ADA for HbA1c (<7.0%) was considerably greater in the presented study in both CSII and MDI groups than in the STAR 3 cohort. The difference was particularly evident in MDI individuals (25.7% vs. 10% reported by STAR 3), undermining the beneficial effect of CSII and suggesting suboptimal diabetes management in the MDI group in the cited study.
Treatment with CSII contributed towards better metabolic control of diabetes in terms of HbA1c level and reduction in its variability. Application of CSII did not affect the rate of acute hospitalizations or the risk of acute hospitalization in comparison with MDI in children with diabetes but was associated with a shorter duration of annual in-hospital stay.
The study was performed as part of the TEAM project financed by the Innovative Economy Programme of the European Union coordinated by the Foundation for Polish Science.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.